A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

By Srkalovic Gordan   Elson Paul   Trebisky Beth   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 219-226

Humana Press, Inc

Access to resources Recommend Favorite

Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma

By Ribas Christian   Colleoni Gisele   Almeida Manuella   Duch Cibele Repele   Ohashi Cláudio   Segreto Roberto   Silva Maria Regina  

Acta Oncologica, Vol. 43, Iss. 2, 2004-03 ,pp. : 215-216

Informa Healthcare

Access to resources Recommend Favorite

A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

By Groves Morris   Puduvalli Vinay   Chang Susan   Conrad Charles   Gilbert Mark   Tremont-Lukats Ivo   Liu Ta-Jen   Peterson Pamela   Schiff David   Cloughesy Timothy   Wen Patrick   Greenberg Harry   Abrey Lauren   DeAngelis Lisa   Hess Kenneth   Lamborn Kathleen   Prados Michael   Yung W.  

Journal of Neuro-Oncology, Vol. 81, Iss. 3, 2007-02 ,pp. : 271-277

Springer Publishing Company

Access to resources Recommend Favorite

Phase trial of granulocyte-macrophage colony-stimulating factor plus thalidomide in older patients with castration-resistant prostate cancer

By      

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 865-868

Science Publishers

Access to resources Recommend Favorite